文献速递产科母胎医学

STATIN试验:竞争风险模型在35-37周妊娠筛查子痫前期的预测性能

STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

本研究基于STATIN研究筛查人群的前瞻性多中心数据,验证既往报道的竞争风险模型在35-37周妊娠筛查子痫前期的预测性能。29 677例单胎妊娠中653例发生子痫前期,联合母体风险因素、MAP、PlGF和sFlt-1(三联检测)在10%假阳性率下检出率为79%(95%CI 76-82%),AUC为0.923(95%CI 0.913-0.932),校准斜率为0.875(95%CI 0.831-0.919)。结论认为该竞争风险模型对足月子痫前期的孕晚期预测有效且可重复。

要点

  • 三联检测(母体因素+MAP+PlGF+sFlt-1)在10%假阳性率下检出79%的子痫前期。
  • 三联检测AUC为0.923,区分能力很高;校准斜率0.875,预测风险与观察发生率一致性良好。
  • 加用UtA-PI并未改善三联检测的预测性能。

核心结论

  • 竞争风险模型为孕晚期预测足月子痫前期提供了有效且可重复的方法。

研究设计与样本

  • 前瞻性多中心第三孕期筛查研究,纳入29 677例单胎妊娠,其中653例发生子痫前期。
  • 采用既往报道的竞争风险模型,结合母体风险因素与生物标志物计算患者特异性风险。
  • 通过AUC、固定10%假阳性率下的检出率以及校准斜率和校准-in-the-large评估预测性能。

主要发现

  • 三联检测(母体风险因素+MAP+PlGF+sFlt-1)在10%假阳性率下检出率为79%(95%CI 76-82%)。
  • 三联检测AUC为0.923(95%CI 0.913-0.932),显示对患病与未患病妊娠的区分度很高。
  • 校准斜率为0.875(95%CI 0.831-0.919),预测风险与观察到的子痫前期发生率一致性良好。
  • 在三联检测基础上加用UtA-PI未改善预测性能。

关键数值与推荐

  • 三联检测在10%假阳性率下检出率79%(95%CI 76-82%),AUC 0.923(95%CI 0.913-0.932)。
  • 校准斜率0.875(95%CI 0.831-0.919)。
  • 加用UtA-PI未改善三联检测的预测。

临床怎么用

  • 孕35-37周可采用母体风险因素联合MAP、PlGF和sFlt-1的竞争风险模型评估足月子痫前期风险。
  • 该模型预测风险与观察发生率一致性良好,可用于孕晚期风险分层。
  • 加用UtA-PI对该模型无额外增益,资源有限时可考虑不纳入。

局限性

  • 本文摘要未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the predictive performance of a previously reported competing-risks model of screening for pre-eclampsia (PE) at 35-37 weeks' gestation by combinations of maternal risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1) in a validation dataset derived from the screened population of the STATIN study. METHODS: This was a prospective third-trimester multicenter study of screening for PE in singleton pregnancies by means of a previously reported algorithm that combines maternal risk factors and biomarkers. Women in the high-risk group were invited to participate in a trial of pravastatin vs placebo, but the trial showed no evidence of an effect of pravastatin in the prevention of PE. Patient-specific risks of delivery with PE were calculated using the competing-risks model, and the performance of screening for PE by maternal risk factors alone and by various combinations of risk factors with MAP, UtA-PI, PlGF and sFlt-1 was assessed. The predictive performance of the model was examined by, first, the ability of the model to discriminate between the PE and no-PE groups using the area under the receiver-operating-characteristics curve (AUC) and the detection rate at a fixed false-positive rate of 10%, and, second, calibration by measurements of calibration slope and calibration-in-the-large. RESULTS: The study population of 29 677 pregnancies contained 653 that developed PE. In screening for PE by a combination of maternal risk factors, MAP, PlGF and sFlt-1 (triple test), the detection rate at a 10% false-positive rate was 79% (95% CI, 76-82%) and the results were consistent with the data used for developing the algorithm. Addition of UtA-PI did not improve the prediction provided by the triple test. The AUC for the triple test was 0.923 (95% CI, 0.913-0.932), demonstrating very high discrimination between affected and unaffected pregnancies. Similarly, the calibration slope was 0.875 (95% CI, 0.831-0.919), demonstrating good agreement between the predicted risk and observed incidence of PE. CONCLUSION: The competing-risks model provides an effective and reproducible method for third-trimester prediction of term PE. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Döbert M, Wright A, Varouxaki AN, et al. STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol. 2022. PMID: 34580947. doi:10.1002/uog.24789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。